GO
Loading...

Enter multiple symbols separated by commas

Cyclacel Pharmaceuticals Inc

  • Dec 16- Cyclacel Pharmaceuticals Inc said an independent committee had determined that its lead drug was unlikely to show a statistically significant improvement in the survival rates in some leukemia patients. The company's stock plunged nearly 69 percent to 89 cents in premarket trading on Tuesday. The Berkeley Heights, New Jersey- based company's stock...

  • Dec 16- Cyclacel Pharmaceuticals Inc said an independent data and safety board determined that its lead drug was unlikely to show a statistically significant improvement in survival in some leukemia patients. The company's stock plunged about 47 percent to $1.49 before the bell on Tuesday. The board is evaluating the company's oral drug, sapacitabine, which...